# Patrice Viens

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 154 papers | 12,608 citations | 47 h-index | 111 g-index |
| 193 ext. papers | 14,130 ext. citations | 5.8 avg, IF | 5.47 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 154 | ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*, **2007**, 1, 555-67 | 18 | 3079 |
| 153 | Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Research*, **2009**, 69, 1302-13 | 10.1 | 938 |
| 152 | Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clinical Cancer Research*, **2010**, 16, 45-55 | 12.9 | 570 |
| 151 | Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. *Journal of Clinical Oncology*, **2006**, 24, 5664-71 | 2.2 | 444 |
| 150 | Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. *Journal of Clinical Investigation*, **2011**, 121, 3609-22 | 15.9 | 391 |
| 149 | How basal are triple-negative breast cancers?. *International Journal of Cancer*, **2008**, 123, 236-40 | 7.5 | 336 |
| 148 | Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. *Journal of Clinical Oncology*, **2007**, 25, 3407-14 | 2.2 | 331 |
| 147 | International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. *Annals of Oncology*, **2011**, 22, 515-523 | 10.3 | 321 |
| 146 | Prognostic and predictive value of PDL1 expression in breast cancer. *Oncotarget*, **2015**, 6, 5449-64 | 3.3 | 313 |
| 145 | Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. *Oncogene*, **2004**, 23, 1377-91 | 9.2 | 265 |
| 144 | Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. *Cancer Research*, **2006**, 66, 4636-44 | 10.1 | 235 |
| 143 | Integrated profiling of basal and luminal breast cancers. *Cancer Research*, **2007**, 67, 11565-75 | 10.1 | 232 |
| 142 | A gene expression signature identifies two prognostic subgroups of basal breast cancer. *Breast Cancer Research and Treatment*, **2011**, 126, 407-20 | 4.4 | 192 |
| 141 | Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. *Cancer Research*, **2005**, 65, 2170-8 | 10.1 | 186 |
| 140 | Recent trends in epidemiology of brain metastases: an overview. *Anticancer Research*, **2012**, 32, 4655-62 | 2.3 | 179 |
| 139 | BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. *Annals of Oncology*, **2012**, 23, 2799-2805 | 10.3 | 156 |
| 138 | Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. *Cancer Research*, **2004**, 64, 8558-65 | 10.1 | 155 |

| | | | |
|---|---|---|---|
| 137 | Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. *Journal of Pathology*, **2004**, 202, 265-73 | 9.4 | 150 |
| 136 | Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. *Cancer Research*, **2005**, 65, 767-79 | 10.1 | 141 |
| 135 | Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. *Journal of the National Cancer Institute*, **2018**, 110, 560-567 | 9.7 | 137 |
| 134 | Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. *Lancet Oncology, The*, **2012**, 13, 375-84 | 21.7 | 134 |
| 133 | Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. *American Journal of Pathology*, **2002**, 161, 1223-33 | 5.8 | 133 |
| 132 | Genome profiling of ERBB2-amplified breast cancers. *BMC Cancer*, **2010**, 10, 539 | 4.8 | 114 |
| 131 | Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. *Blood*, **2004**, 103, 435-41 | 2.2 | 111 |
| 130 | Identification and validation of an ERBB2 gene expression signature in breast cancers. *Oncogene*, **2004**, 23, 2564-75 | 9.2 | 101 |
| 129 | Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. *BMC Cancer*, **2006**, 6, 245 | 4.8 | 100 |
| 128 | PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. *Cancers*, **2019**, 11, | 6.6 | 99 |
| 127 | Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. *Clinical Cancer Research*, **2013**, 19, 4685-96 | 12.9 | 99 |
| 126 | ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. *Cancer Research*, **2013**, 73, 7290-300 | 10.1 | 98 |
| 125 | Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. *Stem Cells*, **2012**, 30, 1327-37 | 5.8 | 97 |
| 124 | Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. *Human Molecular Genetics*, **2002**, 11, 863-72 | 5.6 | 90 |
| 123 | PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. *Oncotarget*, **2015**, 6, 13506-19 | 3.3 | 87 |
| 122 | Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. *Cancer Research*, **2008**, 68, 767-76 | 10.1 | 86 |
| 121 | Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. *Molecular Cancer*, **2014**, 13, 228 | 42.1 | 73 |
| 120 | High-dose chemotherapy for breast cancer: the French PEGASE experience. *Cancer Control*, **2003**, 10, 42-7 | 2.2 | 69 |

| | | | |
|---|---|---|---|
| 119 | Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?. *European Journal of Cancer*, **2012**, 48, 1939-46 | 7.5 | 66 |
| 118 | Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. *Annals of Oncology*, **2014**, 25, 358-65 | 10.3 | 65 |
| 117 | Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. *Haematologica*, **2007**, 92, 1004-6 | 6.6 | 64 |
| 116 | Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. *Molecular and Cellular Proteomics*, **2008**, 7, 1420-33 | 7.6 | 62 |
| 115 | Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. *Breast Cancer Research and Treatment*, **2011**, 127, 273-81 | 4.4 | 58 |
| 114 | Comparative multi-methodological measurement of ERBB2 status in breast cancer. *Journal of Pathology*, **2004**, 202, 286-98 | 9.4 | 58 |
| 113 | Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 483-91 | 4 | 55 |
| 112 | High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?. *Journal of Clinical Oncology*, **2000**, 18, 754-64 | 2.2 | 55 |
| 111 | Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. *Annals of Oncology*, **2013**, 24, 1231-8 | 10.3 | 53 |
| 110 | Comparative genomic analysis of primary tumors and metastases in breast cancer. *Oncotarget*, **2016**, 7, 27208-19 | 3.3 | 53 |
| 109 | Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. *Lancet Oncology, The*, **2012**, 13, 420-32 | 21.7 | 52 |
| 108 | High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. *PLoS ONE*, **2011**, 6, e16950 | 3.7 | 50 |
| 107 | Defining the molecular biology of inflammatory breast cancer. *Seminars in Oncology*, **2008**, 35, 41-50 | 5.5 | 47 |
| 106 | Gene expression profiling and clinical outcome in breast cancer. *OMICS A Journal of Integrative Biology*, **2006**, 10, 429-43 | 3.8 | 47 |
| 105 | How different are luminal A and basal breast cancers?. *International Journal of Cancer*, **2009**, 124, 1338-48 | 7.5 | 46 |
| 104 | Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. *Clinical Cancer Research*, **2015**, 21, 1298-304 | 12.9 | 43 |
| 103 | Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. *PLoS ONE*, **2014**, 9, e81843 | 3.7 | 42 |
| 102 | Gene expression profiling of inflammatory breast cancer. *Cancer*, **2010**, 116, 2783-93 | 6.4 | 42 |

| | | | |
|---|---|---|---|
| 101 | Clinical development of mTOR inhibitors in breast cancer. *Breast Cancer Research*, **2014**, 16, 203 | 8.3 | 41 |
| 100 | Genomic and expression analysis of microdissected inflammatory breast cancer. *Breast Cancer Research and Treatment*, **2013**, 138, 761-72 | 4.4 | 41 |
| 99 | Genomic profiling of inflammatory breast cancer: a review. *Breast*, **2014**, 23, 538-45 | 3.6 | 40 |
| 98 | Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. *Annals of Oncology*, **2017**, 28, 103-109 | 10.3 | 40 |
| 97 | Kinome expression profiling and prognosis of basal breast cancers. *Molecular Cancer*, **2011**, 10, 86 | 42.1 | 40 |
| 96 | Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?. *Annals of Oncology*, **2012**, 23, 714-721 | 10.3 | 40 |
| 95 | Loss, mutation and deregulation of L3MBTL4 in breast cancers. *Molecular Cancer*, **2010**, 9, 213 | 42.1 | 38 |
| 94 | Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?. *Critical Reviews in Oncology/Hematology*, **2010**, 75, 138-50 | 7 | 37 |
| 93 | PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. *European Journal of Cancer*, **2017**, 86, 28-36 | 7.5 | 35 |
| 92 | Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. *American Journal of Pathology*, **2015**, 185, 1022-32 | 5.8 | 35 |
| 91 | Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 600-11 | 21.7 | 35 |
| 90 | Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. *Bone Marrow Transplantation*, **2012**, 47, 549-55 | 4.4 | 34 |
| 89 | Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. *Annals of Oncology*, **2017**, 28, 769-776 | 10.3 | 32 |
| 88 | Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma. *Cancer*, **1999**, 85, 2190-2199 | 6.4 | 32 |
| 87 | Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. *European Respiratory Journal*, **2012**, 39, 172-9 | 13.6 | 31 |
| 86 | MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. *Oncotarget*, **2016**, 7, 18531-40 | 3.3 | 31 |
| 85 | EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. *Cancer Letters*, **2014**, 355, 70-5 | 9.9 | 30 |
| 84 | A seven-gene prognostic model for platinum-treated ovarian carcinomas. *British Journal of Cancer*, **2011**, 105, 304-11 | 8.7 | 28 |

| | | | |
|---|---|---|---|
| 83 | Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. *PLoS ONE*, **2015**, 10, e0123768 | 3.7 | 27 |
| 82 | 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. *PLoS ONE*, **2012**, 7, e37943 | 3.7 | 27 |
| 81 | Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. *International Journal of Gynecological Cancer*, **2015**, 25, 815-22 | 3.5 | 25 |
| 80 | Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. *Clinical Cancer Research*, **2012**, 18, 1555-60 | 12.9 | 25 |
| 79 | Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. *BMC Cancer*, **2010**, 10, 645 | 4.8 | 25 |
| 78 | Full access to medical records does not modify anxiety in cancer patients: results of a randomized study. *Cancer*, **2011**, 117, 4796-804 | 6.4 | 24 |
| 77 | The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. *British Journal of Cancer*, **2018**, 119, 1383-1391 | 8.7 | 23 |
| 76 | Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes. *European Journal of Cancer Care*, **2012**, 21, 242-50 | 2.4 | 22 |
| 75 | Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. *European Journal of Cancer*, **2011**, 47, 1537-45 | 7.5 | 22 |
| 74 | MARCKS protein overexpression in inflammatory breast cancer. *Oncotarget*, **2017**, 8, 6246-6257 | 3.3 | 21 |
| 73 | Patients' regrets after participating in a randomized controlled trials depended on their involvement in the decision making. *Journal of Clinical Epidemiology*, **2012**, 65, 635-42 | 5.7 | 20 |
| 72 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. *Breast Cancer Research*, **2011**, 13, R109 | 8.3 | 18 |
| 71 | A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. *Cancers*, **2019**, 11, | 6.6 | 17 |
| 70 | Young breast cancer patients' involvement in treatment decisions: the major role played by decision-making about surgery. *Psycho-Oncology*, **2013**, 22, 2546-56 | 3.9 | 16 |
| 69 | Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. *International Journal of Cancer*, **2003**, 107, 854-62 | 7.5 | 16 |
| 68 | Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. *PLoS ONE*, **2013**, 8, e81677 | 3.7 | 16 |
| 67 | A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. *Oncotarget*, **2015**, 6, 746-54 | 3.3 | 16 |
| 66 | Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. *Oncotarget*, **2016**, 7, 45649-45655 | 3.3 | 16 |

| | | | |
|---|---|---|---|
| 65 | Assessment of prognostic scores in brain metastases from breast cancer. *Neuro-Oncology*, **2014**, 16, 421-8 | 1 | 15 |
| 64 | Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy. *Breast Journal*, **2012**, 18, 406-14 | 1.2 | 15 |
| 63 | Participants' uptake of clinical trial results: a randomised experiment. *British Journal of Cancer*, **2010**, 102, 1081-4 | 8.7 | 15 |
| 62 | Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience. *Cancer*, **2010**, 116, 2829-36 | 6.4 | 14 |
| 61 | UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. *Annals of Oncology*, **2015**, 26, 1692-7 | 10.3 | 13 |
| 60 | Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. *Annals of Oncology*, **2010**, 21, 1448-1454 | 10.3 | 13 |
| 59 | Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. *Experimental Hematology*, **2010**, 38, 55-60 | 3.1 | 13 |
| 58 | NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. *Molecular Oncology*, **2020**, 14, 504-519 | 7.9 | 13 |
| 57 | Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. *Oncotarget*, **2018**, 9, 33762-33777 | 3.3 | 13 |
| 56 | Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. *Breast Cancer Research and Treatment*, **2012**, 132, 1035-47 | 4.4 | 12 |
| 55 | Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2016**, 51, 1082-6 | 4.4 | 12 |
| 54 | Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. *Journal of Geriatric Oncology*, **2018**, 9, 281-283 | 3.6 | 12 |
| 53 | Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. *Anticancer Research*, **2011**, 31, 1079-86 | 2.3 | 12 |
| 52 | Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67. *Pathobiology*, **2013**, 80, 219-27 | 3.6 | 10 |
| 51 | SPAG5: the ultimate marker of proliferation in early breast cancer?. *Lancet Oncology, The*, **2016**, 17, 863-865 | 27 | 9 |
| 50 | Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer. *Current Medical Research and Opinion*, **2010**, 26, 1065-73 | 2.5 | 9 |
| 49 | BetaHCG secretion by a pulmonary adenocarcinoma. *World Journal of Surgical Oncology*, **2013**, 11, 228 | 3.4 | 8 |
| 48 | Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. *Oncotarget*, **2016**, 7, 79428-79441 | 3.3 | 8 |

| | | | |
|---|---|---|---|
| 47 | Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. *Genome Medicine*, **2021**, 13, 87 | 14.4 | 8 |
| 46 | Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. *Cancer Research and Treatment*, **2018**, 50, 1226-1237 | 5.2 | 8 |
| 45 | Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 363-73 | 4.4 | 7 |
| 44 | Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience. *International Journal of Cancer*, **2010**, 127, 1446-52 | 7.5 | 7 |
| 43 | BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.. *Journal of Clinical Oncology*, **2011**, 29, 4028-4028 | 2.2 | 7 |
| 42 | Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory locally advanced breast cancers. *Oncotarget*, **2017**, 8, 66019-66032 | 3.3 | 7 |
| 41 | METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. *Anticancer Research*, **2016**, 36, 293-9 | 2.3 | 7 |
| 40 | Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI. *American Journal of Roentgenology*, **2016**, 206, 891-900 | 5.4 | 6 |
| 39 | Breast cancer patients' views on the use of genomic testing to guide decisions about their postoperative chemotherapy. *Public Health Genomics*, **2013**, 16, 110-7 | 1.9 | 6 |
| 38 | Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. *Familial Cancer*, **2016**, 15, 497-506 | 3 | 5 |
| 37 | Are there candidates for high-dose chemotherapy in ovarian carcinoma?. *Journal of Experimental and Clinical Cancer Research*, **2012**, 31, 87 | 12.8 | 5 |
| 36 | Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy **2017**, | | 5 |
| 35 | Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). *European Journal of Cancer*, **2017**, 79, 166-175 | 7.5 | 4 |
| 34 | A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. *Supportive Care in Cancer*, **2017**, 25, 2715-2722 | 3.9 | 4 |
| 33 | Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. *European Journal of Cancer*, **2016**, 57, 118-26 | 7.5 | 4 |
| 32 | Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. *Journal of Cancer*, **2016**, 7, 2077-2084 | 4.5 | 4 |
| 31 | Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. *OncoImmunology*, **2021**, 10, 1929724 | 7.2 | 4 |
| 30 | Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France. *Medical Decision Making*, **2017**, 37, 555-566 | 2.5 | 3 |

| | | | |
|---|---|---|---|
| 29 | Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, a monocentric analysis of pre-operative prognosticators. *European Journal of Cancer Care*, **2010**, 19, 827-32 | 2.4 | 3 |
| 28 | Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. *Anti-Cancer Drugs*, **2009**, 20, 946-52 | 2.4 | 3 |
| 27 | Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. *Breast*, **2016**, 27, 8-14 | 3.6 | 3 |
| 26 | Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 2 |
| 25 | REBOUND "Trained to live again": The practice of great Olympic coaches improves and enhances the quality of life of cancer patients in remission after hematopoietic stem cell allogeneic transplantation. *Bone Marrow Transplantation*, **2020**, 55, 997-999 | 4.4 | 2 |
| 24 | Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. *Supportive Care in Cancer*, **2013**, 21, 2359-69 | 3.9 | 2 |
| 23 | Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. *BMC Cancer*, **2015**, 15, 697 | 4.8 | 2 |
| 22 | Carcinomatous myelitis and meningitis after a squamous cell carcinoma of the lip. *Case Reports in Oncology*, **2014**, 7, 33-8 | 1 | 2 |
| 21 | Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. *PLoS ONE*, **2012**, 7, e43409 | 3.7 | 2 |
| 20 | Difference in therapeutic response between basal and nonbasal triple-negative breast cancers. *Oncologist*, **2013**, 18, 1060-1 | 5.7 | 2 |
| 19 | Transparency in the presentation of trial results may not increase patients' trust in medical researchers. *Clinical Trials*, **2012**, 9, 90-3 | 2.2 | 2 |
| 18 | PD03-01: An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC. **2011**, | | 2 |
| 17 | The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. *Expert Review of Anticancer Therapy*, **2017**, 17, 593-606 | 3.5 | 1 |
| 16 | A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. *Chemotherapy*, **2016**, 61, 15-22 | 3.2 | 1 |
| 15 | A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. *Cancers*, **2019**, 11, | 6.6 | 1 |
| 14 | Association of carcinoid tumor and low grade glioma. *World Journal of Surgical Oncology*, **2012**, 10, 236 | 3.4 | 1 |
| 13 | Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. *Breast Cancer Research and Treatment*, **2011**, 129, 401-9 | 4.4 | 1 |
| 12 | Can sequential administration minimise the cost of high dose chemotherapy? An economic assessment in inflammatory breast cancer. *Pharmacoeconomics*, **2003**, 21, 807-18 | 4.4 | 1 |

| | | | |
|---|---|---|---|
| 11 | Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.. *Journal of Clinical Oncology*, **2015**, 33, 108-108 | 2.2 | 1 |
| 10 | High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-8 | 3.6 | 1 |
| 9 | Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. *Npj Breast Cancer*, **2022**, 8, 12 | 7.8 | 0 |
| 8 | Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer **2012**, 243-258 | | |
| 7 | L□prs cancer : mise en place du plan personnalis□de l□prs cancer (PPAC). *Oncologie*, **2011**, 13, 271-276 | 1 | |
| 6 | Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. *Bone Marrow Transplantation*, **2021**, | 4.4 | |
| 5 | Effect of high MMP2 and low MMP9 baseline serum levels on outcome in patients with HER2-positive inflammatory breast cancer (IBC) treated with bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant chemotherapy (NAC) in the BEVERLY 2 study.. *Journal of Clinical Oncology* , **2015**, 33, 600-600 | 2.2 | |
| 4 | Pancreatic neuroendocrine tumors (pNET) in adolescent and young adult (AYA) population: A multi-institutional study of characteristics and outcomes.. *Journal of Clinical Oncology*, **2015**, 33, e15173-e15173 | 2.2 | |
| 3 | Pancreatic adenocarcinoma in adolescent and young adults (18-44): Characteristics and clinical outcomes from Canada and France.. *Journal of Clinical Oncology*, **2015**, 33, e15215-e15215 | 2.2 | |
| 2 | Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study **2012**, 225-242 | | |
| 1 | A study of elite sport-inspired coaching for patients after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 2755-2762 | 4.4 | |